Reportlinker Adds Cystic Fibrosis - Pipeline Assessment and Market Forecasts to 2017

NEW YORK, Aug. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cystic Fibrosis – Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0254469/Cystic-Fibrosis-–-Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Cystic Fibrosis – Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData's pharmaceutical and healthcare report, "Cystic Fibrosis - Pipeline Assessment and Market Forecasts to 2017" is an essential source of information and analysis on the global cystic fibrosis market. The report identifies the key trends shaping and driving the global cystic fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global cystic fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges for the global cystic fibrosis market. Its scope includes:

- Annualized global cystic fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include antibiotics and anti-infective agents, ion transport modulators, anti-inflammatory agents, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, nutritional supplements and Pancreatic Enzyme Replacement Therapy (PERT).

- Analysis of the current and future market competition in the global cystic fibrosis market. Key market players covered are Cystic Fibrosis Foundation Therapeutics, Inc (CFFT), Pharmaxis, Gilead Sciences, Vertex Pharma, AstraZeneca and PARI Pharma.

- Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessments, market characterization, unmet needs and the implications for the future market associated with cystic fibrosis therapeutics.

Reasons to buy

The report will enhance your decision making capability in a rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global cystic fibrosis market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cystic fibrosis market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global cystic fibrosis market landscape? Identify, understand and capitalize.

List of Tables

1.1 List of Tables

Table 1: Cystic Fibrosis Therapeutics Market, Global, Revenue ($m), 2001–2009 8

Table 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenue ($m), 2009–2017 9

Table 3: Major Marketed Products Analysis in Cystic Fibrosis Therapeutics Market, 2010 17

Table 4: Cystic Fibrosis – Most Promising Drugs Under Clinical Development, 2010 20

Table 5: Cystic Fibrosis – Phase III Clinical Pipeline, 2010 25

Table 6: Cystic Fibrosis – Phase II Clinical Pipeline, 2010 26

Table 7: Cystic Fibrosis – Phase I Clinical Pipeline, 2010 28

Table 8: Cystic Fibrosis – Preclinical Pipeline, 2010 29

Table 9: Cystic Fibrosis – Discovery Pipeline, 2010 29

Table 10: Discontinued Drugs for Cystic Fibrosis, 2010 30

Table 11: CFFT – Cystic Fibrosis Marketed Products, 2010 33

Table 12: CFFT – Cystic Fibrosis Pipeline Portfolio, 2010 33

Table 13: Pharmaxis Ltd – Respiratory Marketed Product, 2010 35

Table 14: Pharmaxis Ltd – Respiratory Pipeline Portfolio, 2010 35

Table 15: Gilead Sciences, Inc – Respiratory Pipeline Portfolio, 2010 37

Table 16: Vertex Pharmaceuticals Inc – Respiratory Pipeline Portfolio, 2010 38

Table 17: AstraZeneca – Respiratory Marketed Products, 2010 40

Table 18: AstraZeneca – Respiratory Pipeline Portfolio, 2010 40

Table 19: Pari Pharma – Respiratory Marketed Products, 2010 41

Table 20: Pari Pharma – Respiratory Pipeline Portfolio, 2010 41

List of Figures

1.2 List of Figures

Figure 1: Cystic Fibrosis Therapeutics Market, Global, Revenues ($m), 2001–2009 8

Figure 2: Cystic Fibrosis Therapeutics Market, Global, Forecast Revenues ($m), 2009–2017 9

Figure 3: Opportunity and Unmet Need in Cystic Fibrosis Market, 2010 11

Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Cystic Fibrosis, 2010 12

Figure 5: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline, 2010 19

Figure 6: Technology Trends Analytic Framework of the Cystic Fibrosis Pipeline – Description, 2010 20

Figure 7: Cystic Fibrosis – Clinical Pipeline by Mechanism of Action, 2010 24

Figure 8: Cystic Fibrosis – Pipeline by Phase of Clinical Development, 2010 25

Figure 9: Cystic Fibrosis – Implications for the Future Market Competition, 2010 31

Figure 10: Cystic Fibrosis Therapeutics – Clinical Pipeline by Company , 2010 32

Figure 11: GlobalData Methodology 44

Figure 12: GlobalData Market Forecasting Model 47

Companies Mentioned

Cystic Fibrosis Foundation Therapeutics, Inc.

Pharmaxis Ltd

Gilead Sciences, Inc

Vertex Pharmaceuticals, Inc

AstraZeneca

PARI Pharma

To order this report:

Medical Devices Industry: Cystic Fibrosis – Pipeline Assessment and Market Forecasts to 2017

Medical Devices Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo